Paragon Bioservices has appointed Gerard Fleury as Chief Financial Officer (CFO).
"Our rapid growth, driven by the expanding needs of our client-base over the last few years, has warranted our need to invest in the ranks and capabilities of Paragon's leadership team," said President and CEO of Paragon Bioservices Pete Buzy. "Our focus has been on assembling experts at every level of the organization to expand our capabilities to Phase 3/Commercial to address our clients' continually advancing needs. As our new CFO, Gerard is an important addition to our leadership team who joins Paragon on the heels of several promotions and new executive hires we announced earlier this year."
Fleury is a C-level leader with more than 25 years of experience across multiple industries. Most recently, he was the CFO of Pharmaceutics International (Pii), a privately held CDMO providing dosage form development and manufacturing services to the global pharmaceutical industry, where he was responsible for the strategic and financial health of the company.
Fleury spent the early part of his career with Deloitte & Touche, rising to senior manager in the Emerging Business and Corporate Finance Groups. Since then, he has more than 25 years of experience as a CFO, COO or CEO of companies in the biotech, pharmaceutical, healthcare IT, and software industries. Mr. Fleury has managed organizations through turn-around situations as well as growth and optimization cycles, in companies ranging from pre-revenue to $350 million. He graduated from Towson University where he earned a Bachelor's degree in business administration with a concentration in accounting. He has served on the boards of directors of or as an advisor to software, internet, data center and utility companies.